
    
      Total study duration was up to 34 weeks: screening up to 28 days, treatment phase of 24
      weeks, and post-treatment follow-up of 6 weeks.

      After completion of the treatment phase of this study, participant were eligible to enter a
      long term safety study (LTS11210) for active treatment with SAR153191 (REGN88).
    
  